Fast Track Initiative

RegCell focuses on developing innovative therapies by modulating or controlling the immune system. Its primary objective is to treat patients with autoimmune diseases and cancer.

Neusignal Therapeutics is a biopharmaceutical company dedicated to developing small molecule drugs for the treatment of dementia and psychiatric disorders. Its primary focus lies in researching and developing therapeutic agents aimed at overcoming central nervous system diseases.

Founded in Tokyo, Japan in 2020, Medii is an e-consulting platform that connects medical institutions with specialist doctors. It offers on-site consulting services and online specialist consultations to address regional shortages of specialists.

Founded in Tokyo, Japan in 2016, A10 Lab develops a mobile application that encourages users to build teams of five for mutual support in forming new habits. The app gamifies habit-building and fosters social accountability.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

CellFiber Co., Ltd., established in 2015 and headquartered in Tokyo, Japan, specializes in the development and sale of cell-laden soft materials. The company focuses on creating plug-and-play bio-manufacturing solutions using its proprietary CellFiber™ technology. This technology is designed to enhance yields and product quality, ensuring stability, predictability, reproducibility, and scalability for cell and gene therapy applications. By providing efficient cell mass production processes, CellFiber supports a wide range of applications from research to clinical use, ultimately lowering costs and development timelines.

AIRNA is a biotechnology company specializing in the development of RNA editing therapies. Its platform enables the creation of therapeutics designed to treat both rare and common diseases, with the goal of improving patients' health.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

Varinos Inc. is a clinical testing company based in Tokyo, Japan, founded in 2017. It specializes in genomic testing and continuous clinical sequencing services, partnering with medical institutions to provide advanced contract analysis. Utilizing next-generation sequencing technology, Varinos offers services such as endometrial microbiome testing and flow of intrauterine flora testing. The company's innovative genome analysis capabilities enable the detection of microscopic amounts of bacteria and facilitate the examination of genes and chromosomes in embryos before pregnancy, thereby assisting women in identifying potential abnormalities and reducing associated physical and mental burdens.

reverSASP Therapeutics is focused on developing innovative drugs aimed at treating aging-related diseases by targeting senescent cells. The company leverages its deep understanding of the biology underlying these conditions, particularly the Senescence-associated secretory phenotype (SASP), to create therapeutic solutions. By addressing the challenges posed by declining birthrates and an aging population, reverSASP Therapeutics aims to extend healthy life expectancy and improve the quality of life for older individuals. Its research emphasizes the unique properties of inflammatory senescent cells, which are linked to various age-related diseases, positioning the company as a key player in the field of longevity and healthspan enhancement.

mediPhone, Inc. is a company based in Minato, Japan, specializing in medical interpretation services. Founded in 2014, it aims to eliminate language barriers in healthcare by providing telephone and video medical interpreter services. The company offers a range of solutions, including a medical translation application, assistance with hospitalization guidance, and the dispatch of interpreters for advanced treatments and medical checkups. Through these services, mediPhone facilitates access to healthcare for clients in various regions, ensuring they receive necessary medical care without the challenges posed by language differences.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

Founded in Tokyo, Japan in 2016, A10 Lab develops a mobile application that encourages users to build teams of five for mutual support in forming new habits. The app gamifies habit-building and fosters social accountability.

Fast Doctor operates a digital healthcare platform that provides after-hours emergency and remote medical consultations, including online triage, examinations, prescriptions, and home visits. The service enables patients to access urgent care and routine medical services without visiting a hospital, via a mobile application and a network of partner medical institutions. The company arranges nighttime and holiday doctor visits from partner clinics, addressing common conditions such as vertigo, fever, cough, and injuries, and aims to ease pressure on emergency services while improving accessibility and convenience for patients requiring urgent or routine care. Founded in 2016 and based in Tokyo, Japan.

Braizon Therapeutics, Inc. is a biopharmaceutical company based in Tokyo, Japan, founded in 2015. It focuses on the research and development of innovative drug delivery technologies specifically aimed at treating central nervous system disorders. The company was established through collaborative research efforts led by prominent academics from the University of Tokyo and Tokyo Medical and Dental University. Braizon’s primary objective is to create effective methods for delivering therapeutic drugs across the blood-brain barrier, thereby addressing the challenges associated with treating incurable neuronal diseases. Through its advanced platform, Braizon Therapeutics seeks to enhance the efficacy of treatments for patients suffering from various central nervous system conditions.

Metagen Therapeutics is a drug discovery and development company that leverages microbiome science, with a focus on the gut microbiome to advance pharmaceuticals, healthcare solutions, functional foods, and academic research. Formed as a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., the company aims to unlock microbiome-based therapies and collaborative approaches across industry and academia.

Founded in 2016, RIN Institute is a Japanese biotechnology company dedicated to the research and development of antibody-based medicines and external diagnostic drugs. Its primary focus is on developing monoclonal antibodies for cancer diagnostics and therapeutics.

LUCA Science Inc. is a biotechnology company based in Japan that specializes in developing innovative mitochondrial therapies aimed at restoring cellular bioenergetics in damaged tissues and organs. Utilizing patented iMIT technology, the company creates a novel platform of highly functional mitochondria, which can be supplied to affected areas to enhance bioenergetics and restore normal cellular functions. By harnessing mitochondria as biopharmaceutical agents, LUCA Science aims to address a range of unmet medical needs and improve disease states through the stabilization and control of mitochondrial activity. This groundbreaking approach positions LUCA Science at the forefront of mitochondrial therapy, with the potential to significantly impact the treatment landscape for various health conditions.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

Fast Doctor operates a digital healthcare platform that provides after-hours emergency and remote medical consultations, including online triage, examinations, prescriptions, and home visits. The service enables patients to access urgent care and routine medical services without visiting a hospital, via a mobile application and a network of partner medical institutions. The company arranges nighttime and holiday doctor visits from partner clinics, addressing common conditions such as vertigo, fever, cough, and injuries, and aims to ease pressure on emergency services while improving accessibility and convenience for patients requiring urgent or routine care. Founded in 2016 and based in Tokyo, Japan.

Cytlimic Inc. is a biotechnology company based in Japan, founded on December 16, 2016. The company focuses on the development of cancer peptide vaccines and conducts clinical trials and nonclinical testing for these innovative therapies. Cytlimic's primary aim is to create immunotherapy products that activate the immune system to target and attack cancer cells, allowing patients to maintain a high quality of life during treatment. By leveraging advanced knowledge in cancer immunology, Cytlimic strives to provide effective solutions for overcoming cancer through its investigational vaccines.

PuREC develops innovative cell therapy technologies aimed at enhancing treatment efficacy. The company focuses on rapidly evolving cell therapies and mesenchymal stem cells, targeting specific conditions such as hypophosphatasia (a rare bone formation deficiency) and spinal canal stenosis caused by disc herniation.

Founded in 2016, RIN Institute is a Japanese biotechnology company dedicated to the research and development of antibody-based medicines and external diagnostic drugs. Its primary focus is on developing monoclonal antibodies for cancer diagnostics and therapeutics.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

VELDT Inc. is a Tokyo-based company founded in 2012 that specializes in developing wearable technology and Internet of Things (IoT) products. The company is known for its innovative smartwatches, including the VELDT SERENDIPITY, which combines traditional analog design with modern connectivity features. These devices are designed to help users regain time spent on smartphones, encouraging them to explore their surroundings and discover new experiences. VELDT's products, which also include luxury timepieces, aim to enhance daily routines by providing valuable data related to fitness and health through a blend of transparent light and discreet displays. The company serves a global customer base through retail outlets in Japan and online platforms, gaining recognition for its functional design and clear conceptual approach to technology.

mediPhone, Inc. is a company based in Minato, Japan, specializing in medical interpretation services. Founded in 2014, it aims to eliminate language barriers in healthcare by providing telephone and video medical interpreter services. The company offers a range of solutions, including a medical translation application, assistance with hospitalization guidance, and the dispatch of interpreters for advanced treatments and medical checkups. Through these services, mediPhone facilitates access to healthcare for clients in various regions, ensuring they receive necessary medical care without the challenges posed by language differences.

PENTAS Inc. is a Tokyo-based company founded in 2015 that specializes in the development of medical analysis software and devices. The company's focus includes creating innovative solutions for cerebral aneurysm fluid analysis and the design of intracranial stents. As a subsidiary of Allm Inc., PENTAS is dedicated to advancing medical technology to improve patient outcomes and enhance clinical practices in the field of neurology.

Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.

Yukashikado Inc. is a Tokyo-based company founded in 2013 that specializes in developing personal nutrition testing products. The company offers postal nutrition testing kits that allow individuals to evaluate their nutritional status by analyzing urine samples for various nutrients, including proteins, vitamins, and minerals. By providing results that can be accessed through personal computers and smartphones, Yukashikado enables users to monitor their nutritional levels and make informed decisions about their dietary intake. The company's focus on personal nutrition aims to support overall health and wellness, making it easier for consumers to understand and manage their nutritional needs from the comfort of their homes.

Braizon Therapeutics, Inc. is a biopharmaceutical company based in Tokyo, Japan, founded in 2015. It focuses on the research and development of innovative drug delivery technologies specifically aimed at treating central nervous system disorders. The company was established through collaborative research efforts led by prominent academics from the University of Tokyo and Tokyo Medical and Dental University. Braizon’s primary objective is to create effective methods for delivering therapeutic drugs across the blood-brain barrier, thereby addressing the challenges associated with treating incurable neuronal diseases. Through its advanced platform, Braizon Therapeutics seeks to enhance the efficacy of treatments for patients suffering from various central nervous system conditions.

Alivexis is a private preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates targeting high-value disease conditions. The company leverages advanced computational drug discovery techniques and unique biological insights to expedite the development of new medicines. Its international team comprises experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical, biotechnology, and technology firms. By focusing on innovative approaches, Alivexis aims to enhance biotechnological research and improve the efficiency of delivering essential medicines to patients with unmet medical needs.

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.

CellBank Corp. is a Tokyo-based company founded in 2004 that specializes in cell storage, regenerative medical technology, and the cosmetics sector. The company operates within the framework of regulations governing the safety of regenerative medicine, focusing on innovative solutions in the field. CellBank is dedicated to advancing technologies that support both medical and cosmetic applications, positioning itself as a key player in the intersection of these industries.

Founded in 2016, RIN Institute is a Japanese biotechnology company dedicated to the research and development of antibody-based medicines and external diagnostic drugs. Its primary focus is on developing monoclonal antibodies for cancer diagnostics and therapeutics.

NB Health Laboratory specializes in biotechnology research, focusing on the development of innovative drugs targeting respiratory diseases, chronic inflammation, and infectious diseases. The company is renowned for its expertise in generating functional antibodies targeting G protein-coupled receptors.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

VELDT Inc. is a Tokyo-based company founded in 2012 that specializes in developing wearable technology and Internet of Things (IoT) products. The company is known for its innovative smartwatches, including the VELDT SERENDIPITY, which combines traditional analog design with modern connectivity features. These devices are designed to help users regain time spent on smartphones, encouraging them to explore their surroundings and discover new experiences. VELDT's products, which also include luxury timepieces, aim to enhance daily routines by providing valuable data related to fitness and health through a blend of transparent light and discreet displays. The company serves a global customer base through retail outlets in Japan and online platforms, gaining recognition for its functional design and clear conceptual approach to technology.

VELDT Inc. is a Tokyo-based company founded in 2012 that specializes in developing wearable technology and Internet of Things (IoT) products. The company is known for its innovative smartwatches, including the VELDT SERENDIPITY, which combines traditional analog design with modern connectivity features. These devices are designed to help users regain time spent on smartphones, encouraging them to explore their surroundings and discover new experiences. VELDT's products, which also include luxury timepieces, aim to enhance daily routines by providing valuable data related to fitness and health through a blend of transparent light and discreet displays. The company serves a global customer base through retail outlets in Japan and online platforms, gaining recognition for its functional design and clear conceptual approach to technology.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.

NIL is a bio-tech company that develops innovative and functional ultrafine particle technology based on many years of research experience.

Mental Health Technologies is a company focused on enhancing mental health through various solutions aimed at employees and the broader workforce. It offers standardized measures to support mental well-being, which is a crucial aspect of overall health management. In addition to its mental health solutions, the company also provides medical career support and engages in digital marketing initiatives. By integrating these services, Mental Health Technologies aims to foster a healthier work environment and promote the importance of mental health in professional settings.

NIL provides services including planning, development, maintenance, and sales of various software development tools, research and development linked to software engineering, and more. It also offers services like system and software development, maintenance, sales, and consultation. It offers software tools for use with things like automotive and medical systems.

ReasonWhy Inc., founded on July 7, 2011, is a Japan-based company that specializes in healthcare IT services. The company offers a suite of innovative solutions designed to enhance communication and information access within the medical field. Its key services include Whytlink, a social network tailored for medical professionals; Findme, an online platform that connects patients with doctors for second opinions; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy aims to improve healthcare delivery and facilitate better patient outcomes.

Cytlimic Inc. is a biotechnology company based in Japan, founded on December 16, 2016. The company focuses on the development of cancer peptide vaccines and conducts clinical trials and nonclinical testing for these innovative therapies. Cytlimic's primary aim is to create immunotherapy products that activate the immune system to target and attack cancer cells, allowing patients to maintain a high quality of life during treatment. By leveraging advanced knowledge in cancer immunology, Cytlimic strives to provide effective solutions for overcoming cancer through its investigational vaccines.

NB Health Laboratory specializes in biotechnology research, focusing on the development of innovative drugs targeting respiratory diseases, chronic inflammation, and infectious diseases. The company is renowned for its expertise in generating functional antibodies targeting G protein-coupled receptors.

ReasonWhy Inc., founded on July 7, 2011, is a Japan-based company that specializes in healthcare IT services. The company offers a suite of innovative solutions designed to enhance communication and information access within the medical field. Its key services include Whytlink, a social network tailored for medical professionals; Findme, an online platform that connects patients with doctors for second opinions; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy aims to improve healthcare delivery and facilitate better patient outcomes.

Braizon Therapeutics, Inc. is a biopharmaceutical company based in Tokyo, Japan, founded in 2015. It focuses on the research and development of innovative drug delivery technologies specifically aimed at treating central nervous system disorders. The company was established through collaborative research efforts led by prominent academics from the University of Tokyo and Tokyo Medical and Dental University. Braizon’s primary objective is to create effective methods for delivering therapeutic drugs across the blood-brain barrier, thereby addressing the challenges associated with treating incurable neuronal diseases. Through its advanced platform, Braizon Therapeutics seeks to enhance the efficacy of treatments for patients suffering from various central nervous system conditions.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

PuREC develops innovative cell therapy technologies aimed at enhancing treatment efficacy. The company focuses on rapidly evolving cell therapies and mesenchymal stem cells, targeting specific conditions such as hypophosphatasia (a rare bone formation deficiency) and spinal canal stenosis caused by disc herniation.

CellSeed specializes in regenerative medicine, developing products primarily for Japan and Europe. Its portfolio includes epithelial cell sheets for corneal and esophageal regeneration, cardiac patches for heart diseases, periodontal tissue regeneration, and cartilage sheets for treating osteoarthritis.

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, specializing in the development of innovative cancer immunotherapy drugs. The company is advancing its lead candidate, ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for the treatment of prostate cancer. Additionally, BrightPath is developing GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. The company also has research-stage products, including GRN-1301, a neoantigen targeting drug-resistant tumors in non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Founded in 2003, BrightPath Biotherapeutics aims to stimulate potent immune responses to tumor-associated antigens through its peptide vaccine technology.

ProbeX is a company specializing in the development and manufacturing of molecular imaging technology. It focuses on creating and distributing molecular imaging probe reagents that are essential for drug discovery. In addition to its core products, ProbeX also offers consulting services related to research tools in the field of molecular imaging. Through its innovative solutions, the company aims to advance the capabilities of researchers in various scientific domains.

Japan Medical Information Research Institute focuses on the collection, analysis, and marketing of medical information. The organization provides consulting services to help clients understand and utilize medical data effectively. Through its expertise in medical information, the institute aims to enhance the decision-making processes within the healthcare sector.

CellSeed specializes in regenerative medicine, developing products primarily for Japan and Europe. Its portfolio includes epithelial cell sheets for corneal and esophageal regeneration, cardiac patches for heart diseases, periodontal tissue regeneration, and cartilage sheets for treating osteoarthritis.

Chiome Bioscience is a Japanese biotechnology company founded in 2005 and headquartered in Tokyo. It commercializes the ADLib antibody generation platform, originally developed at RIKEN, and offers services such as antibody production, protein expression, purification, and stable cell line generation for pharmaceutical and academic partners. The company has expanded its focus to include discovery and early‑stage development of therapeutic antibodies for oncology and other diseases, with a pipeline that includes anti‑DLK1, anti‑5T4/WAIF1, anti‑TROP‑2, and anti‑semaphorin‑3A candidates. Chiome collaborates with research institutions, pharmaceutical companies, and has a clinical research capability to advance promising candidates into early trials. The firm has evolved from a platform provider to a drug discovery and development organization, aiming to address unmet medical needs through antibody therapeutics.